The wisdom of screening anybody with nares for MRSA carriage may still be questioned, but one thing is beyond doubt: there’s a lot of money to be made in the screening biz.
Cepheid, which already has a “sole source” contract with the VA healthcare system, just inked contracts with two more integrated delivery systems to start MRSA surveillance programs. With fourth quarter revenues soaring 30% (to almost 50 million dollars), Cepheid’s CEO declared MRSA to be the “key driver” for their increased sales figures. Some of this money is put to use lobbying for bills that mandate MRSA screening, some helps fund “opinion leaders”, consultants and researchers, and some helps investment portfolios grow.
By contrast, the methods Mike outlined for eradicating MRSA from his ICUs do diddly-squat to stimulate the economy.
Subscribe to:
Post Comments (Atom)
OSHA! OSHA! OSHA!
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati... -
This is a guest post by Jorge Salinas, MD, Hospital Epidemiologist at the University of Iowa Hospitals & Clinics. There is virtually no...
-
I’m surprised that we can’t stop arguing about the modes of SARS-CoV-2 transmission, despite the fact that most experts (including our frie...
No comments:
Post a Comment
Thanks for submitting your comment to the Controversies blog. To reduce spam, all comments will be reviewed by the blog moderator prior to publishing. However, all legitimate comments will be published, whether they agree with or oppose the content of the post.